title: Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent.
abstract: The implantation of heparin-coated stents was reported to be well tolerated, but there are conflicting results about acute in-hospital complications. (sub)acute thrombosis rates, and long-term follow-up compared to uncoated stents. We compared the angiographic and clinical results after coronary placement of two stent models: the heparin-coated premounted Jostent and the uncoated premounted NIR stent. Of 710 patients revascularized, a total of 426 patients received Jostent (n = 230) or NIR stent (n = 196) implantation. The primary end points were acute or subacute thrombosis, urgent CABG, AMI or death, while the secondary end points were the comparison of the restenosis rates of the stents at the 6th month and of the functional angina classification of the stent groups at the 1st, 6th and 12th months. There were no significant differences between the Jostent and NIR stent groups regarding angiographic and procedural success. Acute thrombosis rates in the Jostent and NIR stent groups were similar while no subacute thrombosis was observed in either group. The major adverse cardiac event rates of the groups also did not differ. Angiographic restenosis occurred in 17% of the Jostent group and 16% of the NIR stent group (NS). The combined clinical and angiographic restenosis rate was also similar between the Jo and NIR groups (19% and 18%, respectively). Comparison of functional angina classes at the 1st, 6th and 12th months revealed no significant difference between the study groups. In conclusion, when compared with implantation of an uncoated premounted NIR stent, implantation of a heparin-coated premounted Jostent does not provide any more benefit with respect to initial efficacy, sub(acute) thrombosis and 6-month restenosis rates and 12-month clinical outcomes.
authors.affiliation: Department of Cardiology, Pamukkale University Medical School, Denizli, Turkey.
authors.forename: Ender
authors.initials: E
authors.lastname: Semiz
authors.forename: Cengiz
authors.initials: C
authors.lastname: Ermiş
authors.forename: Selim
authors.initials: S
authors.lastname: Yalçinkaya
authors.forename: Oktay
authors.initials: O
authors.lastname: Sancaktar
authors.forename: Necmi
authors.initials: N
authors.lastname: Değer
mesh_terms: D000368:Aged; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage*; D003327:Coronary Disease / Q000601:surgery*; D023903:Coronary Restenosis / Q000209:etiology*; D003328:Coronary Thrombosis / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D012189:Retrospective Studies; D015607:Stents
chemical_list: D020099:Coated Materials, Biocompatible; D006493:Heparin